A synthetic curcumin analogue C66, targeting MAPKs, could decrease HG-induced ACE/Ang II/TGF-β1 both in vitro and in vivo, and attenuated diabetic renal fibrosis and pathological injury in mice, further indicating that C66 is a potential candidate for the treatment of DN. Here, TGFB1 is linked to liver dysplastic nodule.